Is the M&A Frenzy Short-Circuiting Pharma R&D? A Former Researcher Speaks Out

Broadcast in Business

Call in to speak with the host

(347) 996-5894

h:755
s:887431
archived
Pharmaguy

Pharmaguy

×  

Follow This Show

If you liked this show, you should follow Pharmaguy.
A conversation with Kenneth "Eric" Milgram, Ph.D., Principal, Applied Scientific Consulting, former Director, Systems Biology Technologies at Wyeth Pharmaceuticals/Pfizer, about what happens to pharmaceutical companies when they put Wall Street expectations ahead of science-driven innovation.

Comments

 comments